CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Hansa Biopharma

Virtual Investor Event

Autoimmune Deep Dive
Guillain-Barré Syndrome 

Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), who will discuss the unmet need and current treatment landscape for Guillain-Barré syndrome (GBS),  an acute, rare, paralyzing inflammatory disease of the peripheral nervous system.

28 April 2025, 14:00 CEST / 8:00 AM ET

Register and attend

Hansa Medical publishes financial information from its prospectus regarding the new share issue

23 May 2011, 14:30
Regulatory information

On 12 May 2011, Hansa Medical’s annual meeting of shareholders resolved to execute a new share issue of SEK 29 million, with preferential rights to Hansa Medical’s shareholders. Hansa Medical, today, makes official those details which have not been previously published, but which are now available in the new share issue prospectus.

Financial position as at 31 March 2011
The Group’s cash and bank balances amounted at 31 March to just under MSEK 0.1 and equity amounted to MSEK 27.2. Net liabilities amounted to MSEK 9.4, of which MSEK 7.8 was comprised of bridge financing in the form of loans. Short-term liabilities amounted to MSEK 2.3 and were comprised primarily of accounts payable. The attached tables show the Group’s net liabilities as at 31 March 2011.

Files

For further information, please contact:
Emanuel Björne, CEO Hansa Medical AB
Mobile: +46 707 17 54 77
E-mail: [email protected]

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.